GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 50

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, ‘GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016', provides in depth analysis on GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted pipeline therapeutics.

The report provides comprehensive information on the GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)

- The report reviews GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics and enlists all their major and minor projects

- The report assesses GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Overview 7
Therapeutics Development 8
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Products under Development by Stage of Development 8
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Products under Development by Therapy Area 9
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Products under Development by Indication 10
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Products Glance 11
Early Stage Products 11
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Products under Development by Companies 12
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Products under Development by Universities/Institutes 14
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 19
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Companies Involved in Therapeutics Development 21
Aurigene Discovery Technologies Limited 21
Boehringer Ingelheim GmbH 22
Horizon Discovery Group Plc 23
Nimbus Therapeutics, LLC 24
Nuevolution AB 25
PeptiDream Inc. 26
Tosk, Inc. 27
Warp Drive Bio, Inc. 28
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Drug Profiles 29
ARS-853 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
AZD-4785 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
HD-001 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
MM-41 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Oligonucleotide to Inhibit KRAS for Lung Cancer and Colon Cancer - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecule to Inhibit K-RAS for Non-Small Cell Lung Cancer - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecule to Inhibit KRAS for Oncology - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecules 1 to Inhibit K-Ras for Oncology - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules 2 to Inhibit K-Ras for Oncology - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules 3 to Inhibit Ki-Ras for Oncology - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules to Inhibit K-Ras for Oncology - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecules to Inhibit K-Ras for Oncology - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecules to Inhibit KRAS for Oncology - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecules to Inhibit KRas for Solid Tumor - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecules to Inhibit KRAS2B for Oncology - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
SML-8731 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Vaccine to Target K-RAS for Lung Cancer - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Dormant Projects 46
GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Featured News & Press Releases 47
Jul 29, 2014: Researchers Identify Irreversible Inhibitor for KRAS Gene Mutation 47
May 08, 2013: Sentinel Oncology Achieves Milestone In Horizon Discovery Agreement 47
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by Aurigene Discovery Technologies Limited, H2 2016 21
Pipeline by Boehringer Ingelheim GmbH, H2 2016 22
Pipeline by Horizon Discovery Group Plc, H2 2016 23
Pipeline by Nimbus Therapeutics, LLC, H2 2016 24
Pipeline by Nuevolution AB, H2 2016 25
Pipeline by PeptiDream Inc., H2 2016 26
Pipeline by Tosk, Inc., H2 2016 27
Pipeline by Warp Drive Bio, Inc., H2 2016 28
Dormant Projects, H2 2016 46

List of Figures
Number of Products under Development for, H2 2016 8
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Actions, H2 2016 17
Number of Products by Molecule Types, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 19
  • Global DNA Forensic Market Research Report 2018
    Published: 19-Jun-2018        Price: US 2900 Onwards        Pages: 91
    This report studies the global DNA Forensic market status and forecast, categorizes the global DNA Forensic market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China and other regions (India, Southeast Asia, Central & South America, and Middle East & Africa). DNA forensics is a branch of forensic science that focuses on the use of genetic material in criminal investigation to an......
  • Global Somatostatin Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Jun-2018        Price: US 3480 Onwards        Pages: 150
    Somatostatin is one kind of hormone. It is widely distributed throughout the body, especially in the hypothalamus and pancreas. It also acts as an important regulator of endocrine and nervous system function by inhibiting the secretion of several other hormones such as growth hormone, insulin, and gastrin. Scope of the Report: This report focuses on the Somatostatin in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East an......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Somatostatin Market 2018, Forecast to 2023
    Published: 19-Jun-2018        Price: US 4880 Onwards        Pages: 151
    Somatostatin is one kind of hormone. It is widely distributed throughout the body, especially in the hypothalamus and pancreas. It also acts as an important regulator of endocrine and nervous system function by inhibiting the secretion of several other hormones such as growth hormone, insulin, and gastrin. Scope of the Report: This report focuses on the Somatostatin in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East an......
  • 2015-2023 World Biological Safety Testing Market Research Report by Product Type, End-User (Application) and Regions (Countries)
    Published: 16-Jun-2018        Price: US 2800 Onwards        Pages: 112
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Market Segment as follows: By Region / Countries - North America (U.S., Canada, Mexico) - Europe (Germany, U.K., France, Italy, Russia, Spain etc) - South America (Brazil, Argentina etc) - Middle East & Afri......
  • Global Procalcitonin Antibody Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Jun-2018        Price: US 3480 Onwards        Pages: 152
    Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. It can be expressed in E. coli.Procalcitonin Antibody refers to the specific protein which can qualitatively and quantit......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Procalcitonin Antibody Market 2018, Forecast to 2023
    Published: 15-Jun-2018        Price: US 4880 Onwards        Pages: 150
    Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. It can be expressed in E. coli.Procalcitonin Antibody refers to the specific protein which can qualitatively and quantit......
  • Global Epidermal Growth Factor (EGF) (CAS 62253-63-8) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Jun-2018        Price: US 3480 Onwards        Pages: 132
    Epidermal growth factor (EGF) is a growth factor that stimulates cell growth, proliferation, and differentiation by binding to its receptor EGFR. Human EGF is a 6045-Da protein with 53 amino acid residues and three intramolecular disulfide bonds EGF results in cellular proliferation, differentiation, and survival. EGF considerably increases skin cell regeneration. More precisely, they can directly communicate to the skin cells to produce more collagen and elastin, that's why most sk......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Epidermal Growth Factor (EGF) (CAS 62253-63-8) Market 2018, Forecast to 2023
    Published: 15-Jun-2018        Price: US 4880 Onwards        Pages: 136
    Epidermal growth factor (EGF) is a growth factor that stimulates cell growth, proliferation, and differentiation by binding to its receptor EGFR. Human EGF is a 6045-Da protein with 53 amino acid residues and three intramolecular disulfide bonds EGF results in cellular proliferation, differentiation, and survival. EGF considerably increases skin cell regeneration. More precisely, they can directly communicate to the skin cells to produce more collagen and elastin, that's why most sk......
  • Transfer Membrane Market by Type (PVDF, Nitrocellulose, Nylon), Transfer Method (Tank, Semi-dry, Dry), Application (Western, Northern, Southern Blot, Protein Sequencing), End user (Academia, Diagnolab, Pharmaceutical Companies) - Global Forecast to 2023
    Published: 15-Jun-2018        Price: US 5650 Onwards        Pages: 124
    “The global transfer membrane market projected to grow at a CAGR of 1.5%.” The global transfer membrane market is projected to reach 187.9 million by 2023 from USD 174.8 million in 2018, at a CAGR of 1.5%. Factors such as increasing financial support from public and private funding sources for life science research, high prevalence of target diseases across the globe, and increasing research and development expenditure by pharmaceutical and biotechnology ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs